An ongoing dialogue on HIV/AIDS, infectious diseases,
January 20th, 2011
A New Antiretroviral Drug Class, and a Movie
In my email in-box today was a very odd press release, referring to this paper, just published in PLoS ONE. With the subject line, “Koronis – Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug,” it included the following information:
Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism. Koronis is planning a follow-on Phase 2 trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
First, you don’t want to be known as a “Non-suppressive HIV drug.” And second, while I get the premise that giving a drug that leads to mutations probably indicates some sort of selection pressure, it’s a long way from this observation to an actual antiviral agent.
But who knows? This may be the next great antiviral drug class, and the phrase “Viral Decay Acceleration” — with its faint echo of 1950s sci-fi movies — sounds incredibly cool. According to the company’s web site, VDA “exploits the strength of a virus – its high mutation rate – to target its collapse.”
So dim the lights, grab some popcorn, and watch the movie here.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Nurse Scientists as Trusted Voices in Health Communication April 11, 2026Despite the erosion of public confidence in science and medicine, nurses remain highly trusted professionals. Integrating nurse scientists into health communication strategies would benefit public health.
- Intraosseous Abscess from Subacute Osteomyelitis April 11, 2026A 16-year-old girl presented with 1 month of ankle pain and 11 days of fever. Radiographs showed an ill-defined, radiolucent distal tibial lesion; on MRI, the lesion was hypointense and surrounded by a hyperintense sclerotic rim.
- Immunogenicity and Safety of vYF, a Yellow Fever Vaccine — A Phase 2 Trial April 9, 2026In this trial, a new yellow fever vaccine grown in Vero cells was shown to elicit immunogenicity similar to that of the standard yellow fever vaccine.
- Minocycline-Induced Hyperpigmentation April 2, 2026A 68-year-old woman with rosacea presented with a 6-week history of dark patches on the skin of her arms and legs. Two weeks before the onset of the skin changes, she had started taking minocycline daily.
- Legislating Medicine — Directed Donation and the Politics of Patient Choice April 1, 2026A Tennessee bill focused on directed blood donation exemplifies a pattern of efforts to legislate medical practice in ways that override scientific consensus while invoking the language of autonomy.
- Nurse Scientists as Trusted Voices in Health Communication April 11, 2026